Quince Therapeutics, Inc. — Form 8-K
Filed September 14, 2026 · analyzed by the 8-K Agent
8-K
▼ Likely negative
significance 22/100
What the filing says
On September 8, 2026, Quince Therapeutics sold its Italian subsidiary (Quince SPA) and related assets—including IP, equipment (55 units), and systems for autologous intracellular drug encapsulation technology—to Ayma Therapeutics for $450,000. Separately, the company terminated Charles Ryan (employed since 2023) with a severance package totaling $1,014,489.04 (18 months base salary + 150% pro-rated 2026 bonus + 18 months COBRA premiums), payable within 30 days.
Why this rating
Asset sale proceeds ($450K) are 0.7% of market cap; severance ($1.01M) is 1.6% of market cap. Combined divestiture and executive departure signal financial distress but individually routine for small biotech.
Extracted items
- 2.01 acquisition/disposition
See more from September 14, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.